Xenopus‐derived glucagon‐like peptide‐1 and polyethylene‐glycosylated glucagon‐like peptide‐1 receptor agonists: long‐acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities

BACKGROUND AND PURPOSE: Incretin‐based therapies based on glucagon‐like peptide‐1 (GLP‐1) receptor agonists are effective treatments of type 2 diabetes. Abundant research has focused on the development of long‐acting GLP‐1 receptor agonists. However, all GLP‐1 receptor agonists in clinical use or de...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Br J Pharmacol
Autores principales: Han, Jing, Fei, Yingying, Zhou, Feng, Chen, Xinyu, Zhang, Ying, Liu, Lin, Fu, Junjie
Formato: Artigo
Lenguaje:Inglês
Publicado: John Wiley and Sons Inc. 2018
Materias:
Research Papers
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5773971/
https://ncbi.nlm.nih.gov/pubmed/29171021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14107
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares